Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Glaxo

Today, we’re looking at two covered call examples on Pfizer stock. The first step to finding our covered call candidates is to use the Stock Scanner with the following parameters:

Barchart

How to Buy PFE For a 6% Discount, or Achieve a 23% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

Barchart

2 Covered Call Ideas on Pfizer Stock

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

How to Buy PFE For a 7% Discount, or Achieve a 16% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

Barchart

Is the Rally Getting Long in the Tooth? Try These Bear Call Spread Trades

Traders should have a bearish outlook on the stock and ideally look to enter when the stock has a high implied volatility rank.

Barchart

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Benzinga

Stocks Edge Higher, Fed, Salesforce, Pfizer And Elon Musk - 5 Things You Must Know

Stock futures edge higher, but inflation worries linger; Fed begins 'quantitative tightening' with balance sheet run-off; Salesforce shares leap after Q1 earning beat, profit forecast boost; Pfizer to exit consumer healthcare JV with GlaxoSmithKline and Elon Musk weighs-in on work-from-home

The Street

Read news from The Economist, FT, and more,
with one subscription

GlaxoSmithKline Announces $3.3 Billion Buyout To Square Off With Pfizer, Merck

GlaxoSmithKline announced Tuesday a $3.3 billion deal to buy pneumonia vaccine-maker Affinivax. But GSK stock dipped at the close.

Investors Business Daily

GlaxoSmithKline and AstraZeneca secure victories with US drug regulator

GlaxoSmithKline’s drug aimed at chronic kidney disease patients with anaemia and AstraZeneca’s lung cancer treatment have both moved a step closer to getting the green light

Evening Standard

Biotech Feeding Spree As GSK, Halozyme Announce Nearly $3 Billion In Deals

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Investors Business Daily

Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins

GlaxoSmithKline has racked up a series of recent HIV treatment wins and, on Monday, GSK stock flirted with a breakout.

Investors Business Daily

US pulls GSK's COVID drug as omicron sibling dominates cases

U.S. regulators say GlaxoSmithKline’s COVID-19 antibody drug should no longer be used because it is likely ineffective against the latest version of the virus that accounts for most cases

The Independent UK

Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility

GlaxoSmithKline's Covid treatment partner, Vir, will join the S&P SmallCap 600 next week, according to a report that sent Vir stock flying.

Investors Business Daily

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

GSK Stops Additional Three Respiratory Virus Vaccine Trials In Pregnant Women

GlaxoSmithKline Plc (NYSE: GSK) has halte

Evening Standard

Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.

Evening Standard

Under pressure GlaxoSmithKline promises ‘landmark’ year as its outshone by Pfizer

GlaxoSmithKline remained under pressure today after so-so results that drew unfavourable comparisons with US rival Pfizer.

Evening Standard

FTSE 100 Live: Amazon designated a supermarket, Bank of England takes ‘steady hand’, GSK upbeat

GlaxoSmithKline boss Dame Emma Walmsley today promised a “step-change in growth” during a landmark year for the pharma giant.

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

GSK claims $1.2bn victory in HIV patent battle with US rival Gilead

Drugmaker GlaxoSmithKline today claimed a landmark victory in its competitive battle to dominate HIV treatment as a US rival agreed to hand over $1.25 billion to end a high-stakes global patent dispute.

Evening Standard

Unilever’s doomed £50bn GlaxoSmithKline bid was a ‘near-death experience’

Fund manager Terry Smith made a fresh attack on Unilever following the collapse of its bid for GlaxoSmithKline’s consumer-health unit, saying the Dove soap maker needs to focus more on fixing its own business.

Evening Standard

FTSE 100 Live: Unilever latest on Glaxo swoop, Credit Suisse boss quits, China GDP

Shares in Marmite maker Unilever are sharply lower after it made an audacious swoop for GlaxoSmithKline's consumer healthcare arm.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.